Form4insider filings, from the source

SEC Form 4 · accession 0001209191-16-126263

Clearside Biomedical, Inc. · CLSD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Clay Thorp
Director · 10% Owner
John Crumpler
10% Owner
Period of report
Jun 7, 2016
Accepted (ET)
Jun 7, 2016 · 4:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001539029

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2,F3Jun 7, 2016C1,598,219—A1,654,242ISee Footnotes
Common StockF3Jun 7, 2016X21,705$0.022A1,675,947ISee Footnotes
Common StockF3Jun 7, 2016S69$7.00D1,675,878ISee Footnotes
Common StockF3,F5Jun 7, 2016P107,142$7.00A1,783,020ISee Footnotes

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A Preferred StockF3,F6,F2—Jun 7, 2016C2,035,907D——Common Stock925,4110I
Series A-1 Preferred StockF3,F7,F2—Jun 7, 2016C689,388D——Common Stock313,3570I
Series B Preferred StockF3,F8,F2—Jun 7, 2016C432,940D——Common Stock196,7900I
Series C Preferred StockF3,F9,F2—Jun 7, 2016C337,898D——Common Stock162,6610I
Warrant to Purchase Common Stock (right to buy)F3,F11,F10$0.022Jun 7, 2016X19,900DApr 28, 2014—Common Stock19,9000I
Warrant to Purchase Common Stock (right to buy)F3,F12,F10$0.022Jun 7, 2016X1,805DApr 28, 2014—Common Stock1,8050I

Explanation of responses